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ABSTRACT
Background. Video-assisted thoracoscopic surgery
(VATS) approaches are increasingly used in lung cancer
surgery, but little is known about their impact on patients’
health-related quality of life (HRQL). This prospective
study measured recovery and HRQL in the year after
VATS for non-small cell lung cancer (NSCLC) and
explored the feasibility of HRQL data collection in patients
undergoing VATS or open lung resection.
Patients and Methods. Consecutive patients referred for
surgical assessment (VATS or open surgery) for
proven/suspected NSCLC completed HRQL and fatigue
assessments before and 1, 3, 6 and 12 months post-surgery.
Mean HRQL scores were calculated for patients who
underwent VATS (segmental, wedge or lobectomy resec-
tion). Paired t-tests compared mean HRQL between
baseline and expected worst (1 month), early (3 months)
and longer-term (12 months) recovery time points.
Results. A total of 92 patients received VATS, and 18
open surgery. Questionnaire response rates were high (pre-
surgery 96–100%; follow-up 67–85%). Pre-surgery, VATS
patients reported mostly high (good) functional health
scores [(European Organisation for Research and Treat-
ment of Cancer) EORTC function scores [ 80] and low
(mild) symptom scores (EORTC symptom scores \ 20).
One-month post-surgery, patients reported clinically and
statistically significant deterioration in overall health and
physical, role and social function (19–36 points), and
increased fatigue, pain, dyspnoea, appetite loss and con-
stipation [EORTC 12–26; multidimensional fatigue
inventory (MFI-20) 3–5]. HRQL had not fully recovered
12 months post-surgery, with reduced physical, role and
social function (10–14) and persistent fatigue and dyspnoea
(EORTC 12–22; MFI-20 2.7–3.2).
Conclusions. Lung resection has a considerable detri-
mental impact on patients’ HRQL that is not fully resolved
12 months post-surgery, despite a VATS approach.
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Graphic Abstract
Lung resection is a mainstay of therapy for early-stage
lung cancer.1 Resection traditionally involves a thoraco-
tomy, which may be associated with significant mortality
and morbidity.2 Increasingly, video-assisted thoracoscopic
surgery (VATS) approaches have been used;1 whilst data to
support the safety of VATS are available, few well-de-
signed multi-centre studies have compared thoracotomy
and VATS surgery, although studies are ongoing.3 In
addition to understanding mortality and morbidity out-
comes of surgery, the need to assess the impact on aspects
of patients’ health-related quality of life (HRQL) using
validated patient-completed questionnaires has been
increasingly acknowledged.4
Lung resection has been associated with a significant
detrimental impact on patients’ short- to medium-term
HRQL, including reduced physical, role and mental func-
tion and increased pain, in several prospective
observational studies.5–7 Little is still known, however,
about the impact of minimal access lung resection on
HRQL, and the few prospective studies available have
methodological limitations. Larger studies have explored
HRQL after VATS but have been retrospective or cross-
sectional in design and do not measure HRQL pre-opera-
tively.8,9 Prospective studies measuring HRQL before and
after VATS surgery have typically been small in size or
used unvalidated or generic instruments that measure broad
aspects of health, which may not adequately capture the
complex and unique areas of function impaired by lung
cancer6,10–13 or studied few patients.11 Between 2008 and
2014, Bendixen and colleagues14 randomised 206 early-
stage lung cancer patients to open or thoracoscopic
lobectomy in a single centre in Denmark. Patients com-
pleted several measures [EuroQol EQ-5D-3L
questionnaire, a generic measure of health status; EORTC
core quality of life questionnaire (QLQ-C30); pain rating
scale] at baseline and at several time points for 12 months
post-operatively. However, response rates and data com-
pleteness were low, and fatigue, the most common acute
symptom reported by patients before and after lung cancer
treatment,15 was not assessed in detail using a validated
measure. It remains that little is known about the impact of
minimal access lung resection on patients’ HRQL and
whether high-quality self-reported HRQL data can be
collected from this patient group. This prospective study
measured and described in detail the HRQL of patients
before and during the first year after VATS for non-small
cell lung cancer (NSCLC). A secondary aim of the present
work is to explore the feasibility of collecting self-reported
HRQL data in a sample of patients undergoing surgery
(VATS or open lung resection) for NSCLC.
PATIENTS AND METHODS
A prospective questionnaire cohort study was conducted
at a UK academic hospital.
Patients
From May 2014 to April 2015, men and women aged
18 years or over referred to the thoracic surgery service at
University Hospitals Bristol NHS Foundation Trust
(UHBT) for surgical assessment for proven or suspected
NSCLC were screened for study eligibility at the first
surgical consultation following referral. Patients were
excluded if they had previous or concurrent malignancies
or had insufficient capacity or understanding of English to
provide written informed consent.
Routine staging investigations included a computerised
tomography (CT) scan of chest and upper abdomen and
fluorodeoxyglucose positron emission tomography (FDG-
PET) scan. Spirometry and lung carbon monoxide transfer
factor were routinely measured pre-operatively, in accor-
dance with British Thoracic Society guidelines.16 No
patients received adjuvant immunotherapy.
Eligible patients were posted a participant information
leaflet (PIL) after notification of referral for surgical
assessment for proven or suspected lung cancer and a
hospital outpatient appointment for a surgical team con-
sultation, to enable patients time to consider study
participation should they choose to proceed with surgery.
Patients choosing to proceed with surgery at their outpa-
tient consultation were invited to attend the pre-operative
assessment clinic on the same day, where they were
approached by the research nurse about study participation.
Patients expressing an interest were asked by the research
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nurse to give written informed consent for the present
study. Baseline demography and clinical details were col-
lected, and baseline HRQL questionnaires administered.
Ethics committee approval was granted from the West
Midlands–Edgbaston Research Ethics Committee, UK.
Surgery and Peri-operative Care
A team of five consultant thoracic surgeons (T.B., G.C.,
E.I., R.K. and D.W.) from UHBT performed all surgeries
on consenting patients. Thoracoscopic surgery involved
single-lung ventilation, using a 10-mm 30 thoracoscopic
camera and, usually, a total of three thoracoscopic ports.
Lobectomy was performed using an anterior approach
described by Hansen and colleagues.17 Rib spreading was
avoided.
Patients were managed peri-operatively using an insti-
tutional enhanced recovery after surgery (ERAS) pathway,
which included day-of-surgery admission, avoidance of
prolonged fasting, carbohydrate loading, use of minimal
access surgery and regional anaesthesia (when possible),
single chest drains and early mobilisation after surgery.
Patients were given carbohydrate drinks on the morning of
surgery (400 ml Nutritcia preOpTM; Trowbridge, UK), then
daily supplementary drinks until discharge (Fortisips,
Nutricia; Trowbridge, UK). Early mobilisation was
encouraged post-operatively. Post-operative chemotherapy
was offered to patients with good performance status with
node involvement or tumours[ 4 cm diameter.
Consenting patients who subsequently opted out of
surgery or whose diagnosis changed prior to surgery were
excluded. Patients whose surgery was converted from
VATS to open were excluded as it was hypothesised that
HRQL in converted patients was likely to approximate that
of planned open surgery cases. Patients whose diagnosis
changed (e.g. to a benign diagnosis) following pathological
assessment were also excluded as it was hypothesised that
surgery for benign conditions may affect HRQL differently
from those with NSCLC.
Demographic and Clinical Characteristics
of Participants
Demographic, clinical and operative details of eligible
participants undergoing VATS or open surgery were col-
lected, tabulated and analysed using descriptive statistics.
Assessment of Health-Related Quality of Life
in Patients Undergoing Video-Assisted Thoracoscopic
Surgery Lung Resection
HRQL was assessed using two validated questionnaires:
EORTC QLQ-C30 (generic) (version 3.0)18 and EORTC
QLQ-LC13 (lung cancer module).19 The core questionnaire
assesses generic aspects of health, including physical,
emotional and social function and symptoms that com-
monly occur in patients with cancer. The lung cancer
module assesses specific issues related to this group of
patients, including breathlessness, appetite loss and cough,
comprising one symptom scale (dyspnoea) and ten single
items (coughing, haemoptysis, sore mouth, dysphagia,
peripheral neuropathy, alopecia, pain in chest, pain on arm
or shoulder, pain in other parts and pain medication).
EORTC responses were rated on a four-point Likert scale
and transformed linearly to give scores from 0 to 100. In
function scales with multiple items, higher scores indicate a
higher level of functioning, while higher scores on symptom
scales and single items indicate more symptoms. A five-to-
ten-point or greater change in score is considered clinically
significant.20 The validated multidimensional fatigue
inventory MFI-2021 was used to assess fatigue in detail, as
this is the most common acute symptom reported by patients
before and after lung cancer treatment.15 The MFI-20
comprises five dimensions (general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue).
Each dimension includes four items, two that indicate fati-
gue and two that are contradictory of fatigue, rated on a five-
point Likert scale. Scores for the contradictory items were
inverted, and a cumulative score for each dimension was
calculated. Scores for each dimension ranged from 4 to 20.
Higher scores for general, physical and mental fatigue
indicate worse fatigue, whilst higher scores for reduced
activity and reduced motivation indicate greater reduced
activity and motivation. A change in score of C 2 points is
considered clinically relevant.22 A qualitative descriptive
system (e.g. ‘‘good’’, ‘‘moderate’’ and ‘‘poor’’) has not yet
been developed for the interpretation of EORTC scale
scores.23 Reference scores for the patient population inclu-
ded in the present study are not yet available.23 EORTC
scores have therefore been interpreted considering data from
other available published studies.23,24
HRQL assessment points were selected to enable
changes in participants’ HRQL and recovery to be descri-
bed. Participants were asked to complete the first (baseline)
set of questionnaires at their pre-operative assessment
clinic, within 1 month prior to surgery. Participants were
then posted questionnaires at 1, 3, 6 and 12 months post-
surgery. Patients who did not return a questionnaire
received one telephone reminder approximately 3–4 weeks
after the questionnaire was due.
Data Analyses
Questionnaire response rates and reasons for non-com-
pletion were examined using descriptive statistics.
Assessment of the impact on HRQL and recovery from
Quality of Life After VATS for Lung Cancer
either VATS or open surgery was planned a priori. How-
ever, the number of eligible participants receiving open
surgery was too small to enable accurate assessment of
recovery and impact on HRQL. HRQL analyses were
therefore conducted for patients undergoing VATS only.
Mean HRQL scores, standard deviations and 99% confi-
dence intervals were calculated for QLQ-C30, QLQ-LC13
and MFI-20 scales and/or single items at all time points to
describe recovery and the impact of surgery on HRQL
during the first year post-VATS. Paired t-tests were per-
formed post hoc (after seeing the data) to explore
comparisons between baseline HRQL scores and those at
expected worst (1 month), early (3 month) and longer-term
(12 month) recovery time points for scales and items where
changes were considered clinically relevant (C 10-point
change in EORTC scores; C 2-point change in MFI-20
scores).20,22 t-Tests were not performed for the 6-month
time point to minimise the number of statistical tests per-
formed, reducing the probability of a type I error (false-
positive finding). A significance criterion of 1% was used
throughout. Missing data were imputed according to the
EORTC guidelines.25 All analyses were performed using
Stata statistical software version 14.2 (StataCorp, USA).
This study is reported in accordance with the Strength-
ening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines.26
RESULTS
From the 306 patients screened, 164 (54%) were eligible
(Fig. 1); 12 (7.3%) were not enrolled for reasons specified
in Fig. 1, including 5 (3.0%) patients who declined to take
part. No further details were collected on these patients.
From the 152 (93%) patients who consented to participate,
131 (86%) went on to have surgery; 112 (85%) and 19
(15%) were planned for VATS and open surgery, respec-
tively, but 2 were converted from VATS to open resection
during surgery and were subsequently excluded. A further
19 patients whose pathological assessment confirmed
benign lesions were excluded. Therefore, 110 patients were
included in the final analyses [92 (84%) VATS and 18
(16%) open surgery].
Patient Baseline Demographic and Clinical
Characteristics
Baseline (pre-surgery) demographic and clinical details
of the 110 patients who underwent VATS or open surgery
are presented in Supplementary Table S1. Patients selected
for VATS and open surgery were similar in terms of sex,
but appeared to be different in other characteristics: VATS
patients were older (mean age 70 vs 65 years), more often
diagnosed pre-operatively with lower-stage tumours (IA,
IB or IIA 72% vs 33%) and had a better thoracic surgery
scoring system score (Thoracoscore) [median interquartile
range (IQR) 1.5 (1.2, 1.9) vs 2.4 (1.8, 4.5)] than those
selected for open surgery. In addition, patients selected for
VATS were less likely to be obese [body mass index
(BMI) C 30 kg/m2] (33% vs 56%) and more likely to be
current smokers (21% vs 0%).
Patient Peri- and Post-operative Details
Details of the surgical procedure performed and peri-
and post-operative details are provided in Supplementary
Table S2. Longer-term (12-month post-operative) clinical
outcomes are detailed in Supplementary Table S3. At the
end of the 12-month follow-up period, fewer patients
undergoing VATS compared with those undergoing open
surgery had received further treatment for cancer (29% vs
56%), and fewer VATS patients had died (11% vs 33%).
Questionnaire Completion Rates and Reasons
for Withdrawal
Questionnaire response rates at each time point and
reasons for non-completion were included in the analyses
(Table 1). In total, 106/110 (96%) patients completed
HRQL questionnaires pre-surgery, and questionnaire
response rates during follow-up were high, ranging from 67
to 85% at each time point.
Health-Related Quality of Life Before Video-Assisted
Thoracoscopic Surgery Lung Resection
Before VATS (baseline), patients reported high function
scores indicating good overall (global) health and good
physical, role, cognitive and social function, though lower
levels of emotional function (Table 2; Fig. 2). Patients also
reported marked insomnia and fatigue, and mild dyspnoea,
appetite loss and constipation (Table 2; Fig. 3).
Health-Related Quality of Life After Video-Assisted
Thoracoscopic Surgery Lung Resection
Function Scales (EORTC Questionnaires) One month
after VATS, patients’ overall health and physical, role and
social function had deteriorated by a clinically meaningful
amount (C 10 points, 19–36; Table 2; Fig. 2). At 3 months
post-surgery, overall health had recovered to pre-surgery
levels, but problems with reduced physical, role and social
function persisted and were still present 12 months post-
surgery, with a reduction in scores from baseline ranging
from 10 to 14 points.
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Symptom Scales (EORTC Questionnaires) One month
post-surgery, patients reported more pain (25 points),
dyspnoea (25 points), appetite loss (18 points) and
constipation (12 points) on the QLQ-C30 questionnaire
compared with baseline (Table 2; Fig. 3). By 3 months,
problems with pain, appetite loss and constipation had
resolved to baseline levels, though problems with dyspnoea
(22 points) were still present at 12 months. QLQ-LC13
scores also indicated increased levels of dyspnoea
compared with baseline at all follow-up time points,
which had not resolved 12 months post-operatively (15
points; Table 2; Fig. 4). Problems with chest and other
pain measured by the QLQ-LC13 had also increased
1 month after surgery compared with baseline (22 and 17
points, respectively). While problems with other pain had
resolved to pre-surgery levels by 3 months post-surgery,
problems with chest pain were still present (11 points).
Fatigue VATS had the greatest impact on patients’ levels
of fatigue compared with any other symptom or function of
Screened for eligibility
n=306
Eligible patients
n=164
Consenting patients
n=152
Underwent surgery
n=132
Pathologically-confirmed NSCLC
Lobectomy n=69
Sub-lobar n=23
n=110
VATS
n=92
Lobectomy n=11
Pneumonectomy n=7
Open
n=18
Excluded with reasons n=142:
Excluded with reasons n=12:
Excluded with reasons n=20:
Excluded with reasons n=22:
Previous malignancy n=102
Unsuitable for surgery n=9
Highly unlikely to be cancer n=4
Inability to understand English n=2
Change to listed surgery n=1
Learning difficulty preventing participation n=1
Other n=22
Missing n=1
Missed patient n=2
Surgery postponed n=1
Staff sickness n=1
Consenting non-consenter n=3
Other n=5
Unfit for surgery n=9
Did not want surgery n=5
Diagnostic upstaging n=4
Diagnostic change post-mediastinoscopy/
bronchoscopy n=2
Benign tumour n=19
Conversion to open surgery (n=2):
Major bleeding n=1
Pulmonary artery bleeding n=1
Not candidate for radical treatment, biopsy only n=1
FIG. 1 Flow diagram
illustrating eligibility screening
through to surgery for patient
with pathologically confirmed
NSCLC
Quality of Life After VATS for Lung Cancer
T
A
B
L
E
1
E
O
R
T
C
Q
L
Q
-C
3
0
an
d
L
C
-1
3
q
u
es
ti
o
n
n
ai
re
re
sp
o
n
se
ra
te
s
an
d
re
as
o
n
s
fo
r
n
o
n
-c
o
m
p
le
ti
o
n
fo
r
co
n
se
n
ti
n
g
p
at
ie
n
ts
u
n
d
er
g
o
in
g
V
A
T
S
o
r
o
p
en
su
rg
er
y
(n
=
1
1
0
)
B
as
el
in
e
1
m
o
n
th
p
o
st
-s
u
rg
er
y
3
m
o
n
th
s
p
o
st
-s
u
rg
er
y
6
m
o
n
th
s
p
o
st
-s
u
rg
er
y
1
2
m
o
n
th
s
p
o
st
-s
u
rg
er
y
V
A
T
S
O
p
en
A
ll
V
A
T
S
O
p
en
A
ll
V
A
T
S
O
p
en
A
ll
V
A
T
S
O
p
en
A
ll
V
A
T
S
O
p
en
A
ll
E
li
g
ib
le
p
at
ie
n
ts
9
2
1
8
1
1
0
9
1
a
1
8
1
0
9
a
8
9
b
1
6
c
1
0
5
d
8
7
e
1
5
f
1
0
2
g
8
2
h
1
2
i
9
4
j
R
et
u
rn
ed
q
u
es
ti
o
n
n
ai
re
s
(%
)
8
8
(9
5
.7
)
1
8
(1
0
0
)
1
0
6 (9
6
.3
)
7
1
(7
8
.0
)
1
2
(6
6
.7
)
8
3
(7
6
.1
)
6
7
(7
5
.3
)
1
2
(7
5
.0
)
7
9
(7
5
.2
)
7
4
(8
5
.1
)
1
2
(8
0
.0
)
8
6
(8
4
.3
)
6
2
(7
5
.6
)
1
0
(8
3
.3
)
7
2
(7
6
.6
)
Q
u
es
ti
o
n
n
ai
re
n
o
t
se
n
t
d
u
e
to
p
at
ie
n
t
w
it
h
d
ra
w
al
fr
o
m
st
u
d
y
0
0
0
2
0
2
5
1
6
7
1
8
9
1
1
0
Q
u
es
ti
o
n
n
ai
re
n
o
t
se
n
t
d
u
e
to
ad
m
in
is
tr
at
iv
e
er
ro
r
0
0
0
1
0
1
2
0
2
0
0
0
0
0
0
N
o
t
re
tu
rn
ed
fo
r
u
n
k
n
o
w
n
re
as
o
n
2
0
2
1
3
4
1
7
1
3
0
1
3
4
0
4
8
0
8
P
at
ie
n
t
w
it
h
d
re
w
fr
o
m
st
u
d
y
af
te
r
re
ce
iv
in
g
th
e
q
u
es
ti
o
n
n
ai
re
1
0
1
2
1
3
2
0
2
0
0
0
0
0
0
P
at
ie
n
t
to
o
u
n
w
el
l
to
co
m
p
le
te
o
r
d
ie
d
af
te
r
q
u
es
ti
o
n
n
ai
re
w
as
se
n
t
1
0
1
2
1
3
0
3
3
2
2
4
3
1
4
V
A
T
S
v
id
eo
-a
ss
is
te
d
th
o
ra
co
sc
o
p
ic
su
rg
er
y
a
O
n
e
V
A
T
S
p
at
ie
n
t
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
1
-m
o
n
th
fo
ll
o
w
-u
p
b
T
h
re
e
V
A
T
S
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
3
-m
o
n
th
fo
ll
o
w
-u
p
(t
w
o
V
A
T
S
p
at
ie
n
ts
d
ie
d
w
it
h
in
2
8
d
ay
s
o
f
su
rg
er
y
b
u
t
co
m
p
le
te
d
an
d
re
tu
rn
ed
th
ei
r
1
m
o
n
th
fo
ll
o
w
-u
p
q
u
es
ti
o
n
n
ai
re
)
c
T
w
o
o
p
en
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
3
-m
o
n
th
fo
ll
o
w
-u
p
d
F
iv
e
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
3
-m
o
n
th
fo
ll
o
w
-u
p
e
F
iv
e
V
A
T
S
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
6
-m
o
n
th
fo
ll
o
w
-u
p
f T
h
re
e
o
p
en
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
6
-m
o
n
th
fo
ll
o
w
-u
p
g
E
ig
h
t
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
6
-m
o
n
th
fo
ll
o
w
-u
p
h
T
en
V
A
T
S
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
1
2
-m
o
n
th
fo
ll
o
w
-u
p
i S
ix
o
p
en
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
1
2
-m
o
n
th
fo
ll
o
w
-u
p
j 1
6
p
at
ie
n
ts
d
ie
d
b
et
w
ee
n
su
rg
er
y
an
d
1
2
-m
o
n
th
fo
ll
o
w
-u
p
K. N. L. Avery et al.
T
A
B
L
E
2
M
ea
n
s
an
d
9
9
%
co
n
fi
d
en
ce
in
te
rv
al
s
fo
r
E
O
R
T
C
Q
L
Q
-C
3
0
,
E
O
R
T
C
Q
L
Q
-L
C
1
3
an
d
M
F
I-
2
0
q
u
es
ti
o
n
n
ai
re
sc
o
re
s
at
ea
ch
as
se
ss
m
en
t
ti
m
e
p
o
in
t
fo
r
p
at
ie
n
ts
u
n
d
er
g
o
in
g
V
A
T
S
V
ar
ia
b
le
B
as
el
in
e
1
m
o
n
th
p
o
st
-s
u
rg
er
y
3
m
o
n
th
s
p
o
st
-s
u
rg
er
y
6
m
o
n
th
s
p
o
st
-s
u
rg
er
y
1
2
m
o
n
th
s
p
o
st
-s
u
rg
er
y
N
a
M
ea
n
9
9
%
C
Ib
N
M
ea
n
9
9
%
C
I
N
M
ea
n
9
9
%
C
I
N
M
ea
n
9
9
%
C
I
N
M
ea
n
9
9
%
C
I
Q
L
Q
-C
3
0
G
lo
b
al
h
ea
lt
h
an
d
fu
n
ct
io
n
al
sc
al
es
c
G
lo
b
al
h
ea
lt
h
8
8
7
1
.9
6
6
.3
,
7
7
.5
6
4
5
3
.3
4
5
.7
,
6
0
.8
6
3
6
3
.5
5
8
.3
,
6
8
.7
7
1
6
3
5
7
.4
,
6
8
.7
6
0
6
5
.3
5
9
.3
,
7
1
.2
P
h
y
si
ca
l
fu
n
ct
io
n
8
8
8
4
.9
8
0
.0
,
8
9
.8
7
1
6
3
.9
5
7
,
7
0
.8
6
6
6
8
.8
6
2
.3
,
7
5
.3
7
3
6
8
.9
6
2
.4
,
7
5
.4
6
2
7
3
.5
6
7
.3
,
7
9
.7
R
o
le
fu
n
ct
io
n
8
8
8
2
.2
7
4
.4
,
9
0
.0
7
1
4
6
.5
3
6
.3
,
5
6
.7
6
6
6
1
.1
5
2
.4
,
6
9
.8
7
3
6
2
.8
5
3
.8
,
7
1
.8
6
2
6
8
5
8
.4
,
7
7
.6
E
m
o
ti
o
n
al
fu
n
ct
io
n
8
8
7
3
.5
6
7
.4
,
7
9
.6
6
4
7
0
.7
6
2
.3
,
7
9
.1
6
3
7
4
.7
6
7
.1
,
8
2
.4
7
1
7
6
6
9
.0
,
8
3
.0
6
0
7
9
7
1
.9
,
8
6
.2
C
o
g
n
it
iv
e
fu
n
ct
io
n
8
8
8
3
.9
7
9
.0
,
8
8
.8
6
4
7
9
.2
7
1
.6
,
8
6
.7
6
3
8
0
.7
7
4
.7
,
8
6
.6
7
1
8
1
.9
7
5
.3
,
8
8
.6
6
0
7
9
.7
7
2
.3
,
8
7
.2
S
o
ci
al
fu
n
ct
io
n
8
8
8
6
.9
8
0
.5
,
9
3
.4
6
4
6
2
.8
5
2
.2
,
7
3
.3
6
3
7
4
.6
6
6
.3
,
8
2
.9
7
1
7
1
.1
6
1
.6
,
8
0
.7
6
0
7
6
.7
6
7
.1
,
8
6
.2
S
y
m
p
to
m
sc
al
es
/i
te
m
sd
F
at
ig
u
e
8
8
2
3
.7
1
7
.6
,
2
9
.9
7
0
4
9
.2
4
1
.3
,
5
7
.1
6
6
4
0
.3
3
3
.5
,
4
7
.2
7
3
3
9
.1
3
1
.7
,
4
6
.6
6
2
3
5
.3
2
7
.3
,
4
3
.3
N
au
se
a/
v
o
m
it
in
g
8
8
4
.0
1
.1
,
6
.8
7
1
9
.6
3
.6
,
1
5
.6
6
6
8
.3
3
.0
,
1
3
.7
7
2
6
.9
2
.1
,
1
1
.8
6
2
6
.5
1
3
.,
1
1
.6
P
ai
n
8
8
1
6
.5
9
.4
,
2
3
.5
7
1
4
1
.1
3
1
.6
,
5
0
.6
6
6
2
5
.8
1
6
.4
,
3
5
.1
7
3
2
3
.5
1
5
.4
,
3
1
.7
6
3
2
2
.5
1
3
.3
,
3
1
.7
D
y
sp
n
o
ea
8
7
2
4
.1
1
7
.6
,
3
0
.7
7
1
4
8
.8
3
9
.3
,
5
8
.3
6
5
4
5
.6
3
6
.6
,
5
4
.7
7
1
4
7
3
8
.2
,
5
5
.7
6
2
4
5
.7
3
5
.5
,
5
5
.9
In
so
m
n
ia
8
7
3
1
.4
2
1
.5
,
4
1
.3
7
1
4
0
.8
2
9
.2
,
5
2
.5
6
6
3
3
.8
2
3
.1
,
4
4
.6
7
3
3
0
.1
2
0
.4
,
3
9
.9
6
2
2
8
.5
1
7
.9
,
3
9
.1
A
p
p
et
it
e
lo
ss
8
8
1
1
.7
6
.6
,
1
6
.9
7
1
2
9
.6
1
8
.6
,
4
0
.6
6
6
1
7
.7
9
.3
,
2
6
.0
7
2
1
1
.6
4
.8
,
1
8
.4
6
2
1
4
6
.5
,
2
1
.5
C
o
n
st
ip
at
io
n
8
8
1
3
.3
6
.1
,
2
0
.4
6
4
2
5
1
3
.5
,
3
6
.5
6
3
2
1
.2
1
1
.3
,
3
1
.0
7
1
1
3
.6
6
.2
,
2
1
.0
6
0
1
3
.9
6
.2
,
2
1
.6
D
ia
rr
h
o
ea
8
8
7
.2
1
.6
,
1
2
.8
6
3
1
1
.1
2
.4
,
1
9
.8
6
2
8
.6
1
.9
,
1
5
.3
7
1
8
.9
2
.8
7
,
1
5
.0
6
0
6
.1
1
.2
,
1
1
.1
F
in
an
ci
al
p
ro
b
le
m
s
8
8
7
.2
2
.2
,
1
2
.2
6
4
1
3
4
.1
,
2
2
.0
6
2
1
2
.4
4
.7
,
2
0
.1
7
0
1
5
.2
7
.1
,
2
3
.4
6
0
1
3
.9
5
.4
,
2
2
.4
Q
L
Q
-L
C
1
3
S
y
m
p
to
m
sc
al
es
/i
te
m
sd
D
y
sp
n
o
ea
8
6
1
8
.7
1
3
.9
,
2
3
.6
6
3
3
6
.2
2
7
.6
,
4
4
.7
6
3
3
3
.7
2
6
.2
,
4
1
.2
6
8
3
4
.6
2
6
.7
,
4
2
.6
6
2
3
3
.9
2
5
.4
,
4
2
.4
C
o
u
g
h
in
g
8
7
3
5
.2
2
8
.6
,
4
1
.9
7
0
3
7
.6
3
0
.5
,
4
4
.8
6
6
3
4
.9
2
7
.9
,
4
1
.9
7
2
3
6
.1
2
8
.4
,
4
3
.9
6
3
3
4
.4
2
5
.4
,
4
3
.4
H
ae
m
o
p
ty
si
s
8
6
3
.5
0
.2
,
6
.8
7
0
7
.6
1
.9
,
1
3
.4
6
7
1
-0
.9
,
2
.9
7
2
1
.9
-0
.6
,
4
.3
6
3
0
0
.0
,
0
.0
S
o
re
m
o
u
th
8
6
5
.4
1
.4
,
9
.5
7
0
1
0
.5
2
.5
,
1
8
.4
6
7
7
.5
1
.9
,
1
3
.1
7
2
5
.1
1
.3
,
8
.9
6
3
7
.4
1
.9
,
1
2
.9
D
y
sp
h
ag
ia
8
7
3
.8
0
.5
,
7
.2
7
0
1
0
.5
3
.0
,
1
8
.0
6
7
8
.5
1
.6
,
1
5
.3
7
1
6
.1
1
.0
,
1
1
.2
6
3
6
.4
1
.1
,
1
1
.6
P
er
ip
h
er
al
n
eu
ro
p
at
h
y
8
7
1
1
.1
5
.3
,
1
7
.0
7
0
1
0
4
.0
,
1
6
.1
6
5
9
.7
2
.8
,
1
6
.7
7
0
1
5
.7
8
.4
,
2
3
.1
6
2
1
9
.4
1
1
.1
,
2
7
.7
A
lo
p
ec
ia
8
7
4
.2
0
.8
,
7
.7
6
8
1
.5
-0
.8
,
3
.7
6
6
4
.6
0
.3
,
8
.8
7
2
1
0
.7
3
.7
,
1
7
.6
6
2
3
.8
-0
.8
,
8
.4
P
ai
n
in
ch
es
t
8
7
1
0
.7
5
.7
,
1
5
.8
7
0
3
2
.9
2
3
.8
,
4
1
.9
6
6
2
1
.7
1
3
.7
,
2
9
.7
7
1
1
9
.3
1
1
.4
,
2
7
.1
6
2
1
9
.4
1
1
.1
,
2
7
.7
P
ai
n
in
ar
m
8
6
1
2
.8
6
.1
,
1
9
.5
6
9
2
0
.8
1
1
.3
,
3
0
.3
6
6
1
6
.2
7
.0
,
2
5
.4
7
1
1
7
.8
9
.0
,
2
6
.7
6
3
1
8
1
0
.5
,
2
5
.4
P
ai
n
o
th
er
8
4
1
1
.9
7
.3
,
1
6
.5
6
7
2
8
.4
2
4
.5
,
3
2
.2
6
6
1
8
.2
1
2
.7
,
2
3
.6
7
1
1
5
9
.8
,
2
0
.3
6
1
1
7
.5
1
1
.8
,
2
3
.2
M
F
I-
2
0
F
at
ig
u
e
d
im
en
si
o
n
se
G
en
er
al
fa
ti
g
u
e
8
6
9
.7
8
.5
,
1
0
.9
6
6
1
3
.5
1
2
.3
,
1
4
.7
6
4
1
3
.2
1
1
.8
,
1
4
.5
7
1
1
2
.4
1
1
.0
,
1
3
.8
5
7
1
2
.4
1
0
.7
,
1
4
.0
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HRQL. One month after surgery, patients reported a
26-point increase in QLQ-C30 fatigue scores compared
with baseline (Table 2; Fig. 3). Patients’ fatigue scores on
four of the five MFI-20 dimensions (general fatigue,
physical fatigue, reduced activity and reduced motivation)
had also increased by between 2.9 and 5.0 points compared
with baseline, though levels of mental fatigue remained
similar (Table 2; Fig. 5). While problems with reduced
motivation had recovered to pre-surgery levels by
3 months, patients reported persistent problems with
reduced activity (3.2-point difference) and general (2.7
points) and physical fatigue (3 points) on the MFI-20 that
were still present 12 months after surgery. EORTC QLQ-
C30 scores also showed that clinically significant increases
in patients’ problems with fatigue had not resolved during
the first year post-surgery.
Post hoc paired t-tests comparing mean scores between
baseline and expected worse (1 month), early (3 month)
and longer-term (12 months) recovery time points showed
that all clinically significant differences in function,
symptom and fatigue scores observed (described above)
were statistically significant at the 1% significance level
(P\ 0.01 for all, Table 2).
DISCUSSION
This prospective cohort study describes recovery and
impact of surgery on HRQL in patients in the first year
after VATS lung resection for NSCLC. Patient-reported
HRQL assessment using established and validated generic
and disease-specific instruments at multiple time points
provides a detailed understanding of patients’ recovery
after VATS resections to be determined. Patients selected
for lung resection by VATS reported significant worsening
of several symptoms and reduction in many aspects of
HRQL 1 month after surgery. While many problems had
resolved by 3 months post-surgery, patients reported sig-
nificant ongoing reductions in physical, role and social
function, and persistent fatigue and dyspnoea that had still
not recovered 12 months post-surgery.
This study also demonstrates that HRQL data collection
in patients undergoing surgery for NSCLC is possible.
Questionnaire response rates and levels of data complete-
ness in the present study were high at all assessment time
points, and participant withdrawals infrequent. The study
demonstrates that HRQL data can be collected compre-
hensively in future trials.
The present work indicates that the use of VATS
approaches to lung cancer resection instead of open surgery
does not prevent significant and prolonged HRQL changes,
and that the detrimental impact of VATS lung resection on
the HRQL of patients with NSCLC may be more extensive
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and prolonged than previously thought. Symptoms of
dyspnoea and fatigue, in particular, persisted to the end of
follow-up, highlighting areas where future interventions to
improve HRQL might be directed. This finding contrasts
with earlier studies.10,11,14 Bendixen and colleagues for
example described self-reported HRQL of VATS lobec-
tomy patients as high during 12 months of follow-up,
though this was assessed by the generic EuroQol EQ-5D-
3L questionnaire, fatigue and lung cancer-specific HRQL
were not evaluated in detail, and response rates and data
completeness were low.14
Established and validated patient-reported outcome
measures were used to measure HRQL in this study, and
questionnaire response rates and levels of data complete-
ness were high. The present work, however, is a single-
centre prospective cohort study, with patients selected for
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FIG. 2 Mean EORTC QLQ-C30 function scores for patients
undergoing VATS. Higher scores for measures of function (global
health–social function) suggest a higher level of function. A variable
that scored at least 10 points greater or less than the baseline score is
considered clinically relevant
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FIG. 3 Mean EORTC QLQ-C30 symptom scores for patients
undergoing VATS. Higher scores for symptom scales/items
(fatigue–pain other) suggest an increased effect of these symptoms
on patients. A variable that scored at least 10 points greater or less
than the baseline score is considered clinically relevant
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surgery by thoracic surgeons working within lung cancer
multidisciplinary teams, and consequently, it is possible
that the characteristics of the patient sample included do
not reflect those of the wider population of patients
undergoing VATS for NSCLC. This study included
patients diagnosed with stage IA–IV lung cancer and
patients who underwent surgery for locally advanced or
oligometastatic NSCLC. In accordance with current prac-
tice, a minority (approximately 30% of all VATS patients
in this study) underwent adjuvant chemotherapy after sur-
gery. Literature indicates that post-operative chemotherapy
has a significant impact on patients’ HRQL,27 and this
should be considered when interpreting the study findings.
Patients whose surgery was converted from VATS to open
or whose diagnosis changed (e.g. to a benign diagnosis)
following pathological assessment were excluded. Two
patients were converted from VATS to open surgery due to
major bleeding, approximating the 5% conversion rate
reported in national audit data.1 The analysis therefore
describes HRQL only in successfully completed VATS
cases. By using this approach, the impact on HRQL seen
after VATS surgery is independent of the conversion rate.
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FIG. 4 Mean EORTC QLQ-LC13 symptom scores for patients
undergoing VATS. Higher scores for symptom scales/items (fatigue–
pain other) suggest an increased effect of these symptoms on patients.
A variable that scored at least 10 points greater or less than the
baseline score is considered clinically relevant
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FIG. 5 Mean MFI-20 cumulative fatigue scores for patients
undergoing VATS. Higher scores for fatigue dimensions suggest an
increase in sub-scales of fatigue (general, physical and mental) and
increased reduction in activity and motivation. A variable that scored
at least 2 points greater or less than the baseline score is considered a
clinically important difference
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Since one of the main objectives of the present work is to
inform future randomised trial designs, and the conversion
rate might be expected to change over time, this was felt to
be reasonable.
Patients with benign conditions were excluded because
it was hypothesised that HRQL may be impacted differ-
ently for patients undergoing surgery for benign conditions.
Future studies may wish to explore possible differences in
HRQL between patients undergoing surgery for benign and
malignant conditions. Larger studies are also needed to
study subgroups accurately and in detail for example
patients undergoing VATS surgery followed by adjuvant
chemotherapy or patients undergoing sub-lobar lung
resections. The age and gender of the included participants
are, however, broadly similar to those included in the study
by Bendixen et al.,14 although the latter included patients
with early-stage disease only. Comparisons (t-tests)
between HRQL scores at baseline and follow-up time
points were undertaken post hoc, and the sample size was
not specifically powered to accurately and reliably detect
meaningful differences in HRQL scores between time
points. It is possible, therefore, that this may have resulted
in false-negative findings (type II error). In addition,
though a significance criterion of 1% was used throughout,
it is possible that multiple significance testing may have
resulted in false-positive findings (type I error).
While assessment of the HRQL impact of open surgery
was planned a priori, the small number of participants
receiving open surgery meant that accurate assessment
was not possible. Baseline patient characteristics indicated
that patients undergoing VATS surgery were more often
diagnosed pre-operatively with lower-stage tumours, had
a better Thoracoscore, were more likely to be older and
current or recent smoker and less likely to be obese than
patients undergoing open surgery. The open group also
included a greater proportion of pneumonectomies com-
pared with the VATS group. Literature suggests that
pneumonectomies are associated with inferior post-oper-
ative HRQL.11 This shows how participants were selected
differently for each procedure. Consequently, a post hoc
decision was taken not to evaluate the HRQL data in this
group, to avoid unreliable comparisons with the VATS
group regarding HRQL that may result in misleading
conclusions being drawn from the data. Summary data
describing the baseline demographic and clinical charac-
teristics, and post-operative and 12-month follow-up
clinical outcomes are, however, still presented for trans-
parency and to make available information about all
participants recruited for this study that may be of interest
to the reader to interpret the study findings and design
future studies. These data may also be of use to inform
the design of future studies in this field. Participant
numbers were also too small to enable an accurate
comparative assessment of recovery and HRQL according
to the magnitude of VATS resection performed (e.g. to
compare patients undergoing lobectomy or sub-lobar
resections). Nevertheless, the data in this manuscript
provide a foundation for future work in a larger cohort of
patients to explore the impact of the magnitude of
resections on patients’ HRQL. Further work to evaluate
HRQL in a larger sample of participants undergoing
VATS and open surgery is currently taking place in the
ongoing multicentre VIOLET randomised trial
(ISRCTN13472721).28
Assessment of patient-reported HRQL can enable in-
depth understanding of patients’ experiences of recovery
after VATS for NSCLC that is critical to promote patient-
centred care and guide clinical decision-making alongside
clinical and survival data.29,30 Rigorous assessment of
HRQL using validated and multidimensional outcome
measurement instruments is also central to providing
patients with accurate and detailed information about
expected recovery and impact on HRQL and the process of
fully informed consent for surgery.30 Clinicians may con-
sider communicating this information in discussions with
patients prior to surgery.
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